Sort
64,565 grants matching “drug discovery”
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
$480,738Michael J Eck · Dana-Farber Cancer Inst · R01 · FY2022 · CA
KEY TECHNOLOGIES FOR NANOSCALE ASSAYS
$480,736Harvard University (Medical School) · P01 · FY2000 · CA
High Performance Computer System for Biomolecular and Systems Modeling
$480,726Jason Robert Banfelder · Weill Medical Coll Of Cornell Univ · S10 · FY2010 · RR
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors
$480,710Karen M Cichowski · Brigham And Women'S Hospital · U01 · FY2022 · CA
Biosynthesis of marine terpenoid natural products
$480,689Bradley S Moore · University Of California, San Diego · R01 · FY2025 · GM
Cancer Heterogeneity, Immunity, and Microenvironment (CHIME) Training Program
$480,684Diana Clare Hargreaves · Salk Institute For Biological Studies · T32 · FY2025 · CA
A Novel high resolution MS platform for high-throughput screening of G protein-coupled receptors
$480,681Jon Jacobs · Battelle Pacific Northwest Laboratories · R01 · FY2025 · GM
Drug Action, Metabolism and Kinetics
$480,673William M Atkins · University Of Washington · T32 · FY2016 · GM
Structural basis of specificity in affinity-labeled polyketide synthase didomains
$480,656Janet L Smith · University Of Michigan At Ann Arbor · R01 · FY2011 · GM
Univ of Guam/Cancer Res Center of Hawaii Partnership
$480,637University Of Guam · U56 · FY2004 · CA
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
$480,634James K Turkson · University Of Hawaii At Manoa · R01 · FY2016 · CA
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
$480,634James K Turkson · University Of Hawaii At Manoa · R01 · FY2015 · CA
PRECLINICAL CYCLOSPORIN A THERAPY TRIALS FOR PEDIATRIC TBI
$480,633Susan Sheps Margulies · University Of Pennsylvania · U01 · FY2014 · NS
Nuclear transport as a molecular and cellular vulnerability in AD
$480,625Timothy J Mitchison · Harvard Medical School · R21 · FY2021 · AG
Treatment and Prevention of Systemic Candidiasis
$480,625Suzanne M Noble · University Of California, San Francisco · R33 · FY2019 · AI
Drug Resistant Pathways in Relapsed Acute Lymphoblastic Leukemia(ALL)
$480,601William L. Carroll · New York University School Of Medicine · R01 · FY2011 · CA
Next-Generation Antibody Discovery and Development Technology
$480,577David Scott Johnson · Gigagen, Inc. · R44 · FY2017 · CA
Legacy continuation of the KU CMLD Mission
$480,539Thomas Edward Prisinzano · University Of Kansas Lawrence · R24 · FY2016 · GM
Genetic Susceptibility To Carcinogens
$480,500Douglas Bell · National Institute Of Environmental Health Sciences · ZIA · FY2019 · ES
Development of SecA as an Antimicrobial Target
$480,478Cubist Pharmaceuticals, Inc. · R44 · FY2001 · AI
E3 ubiquitin ligase RNF145 in airway smooth muscle functions and in asthma
$480,477Pawan Sharma · Temple Univ Of The Commonwealth · R01 · FY2025 · HL
Targeting MicroRNAs to Eradicate Leukemia Stem Cells
$480,469Ya-Huei Kuo · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Innate Determinants of Microbial Immunity
$480,448Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Inhibition of Bcl-xL by Targeted Degradation
$480,430Guangrong Zheng · University Of Florida · R01 · FY2024 · CA
Collaborative Research: Impacts of the African Origin of Plasmodium vivax on Contemporary Parasite Populations
$480,406Jonathan J Juliano · Univ Of North Carolina Chapel Hill · R01 · FY2017 · TW